Logo image of EXEL

EXELIXIS INC (EXEL) Stock Price, Quote, News and Overview

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD

42.86  -0.86 (-1.97%)

After market: 43.25 +0.39 (+0.91%)

EXEL Quote, Performance and Key Statistics

EXELIXIS INC

NASDAQ:EXEL (5/22/2025, 7:57:41 PM)

After market: 43.25 +0.39 (+0.91%)

42.86

-0.86 (-1.97%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High48.85
52 Week Low20.14
Market Cap11.81B
Shares275.58M
Float269.27M
Yearly DividendN/A
Dividend YieldN/A
PE19.48
Fwd PE15.78
Earnings (Next)08-04 2025-08-04/amc
IPO04-11 2000-04-11


EXEL short term performance overview.The bars show the price performance of EXEL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15 20

EXEL long term performance overview.The bars show the price performance of EXEL in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of EXEL is 42.86 USD. In the past month the price increased by 15.18%. In the past year, price increased by 108.36%.

EXELIXIS INC / EXEL Daily stock chart

EXEL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.77 322.91B
AMGN AMGEN INC 13.1 146.19B
GILD GILEAD SCIENCES INC 13.79 132.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.58B
REGN REGENERON PHARMACEUTICALS 13.47 64.44B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.59B
ARGX ARGENX SE - ADR 99.05 35.50B
ONC BEIGENE LTD-ADR 5.93 25.74B
BNTX BIONTECH SE-ADR N/A 23.82B
NTRA NATERA INC N/A 20.73B
SMMT SUMMIT THERAPEUTICS INC N/A 19.14B
BIIB BIOGEN INC 7.98 18.51B

About EXEL

Company Profile

EXEL logo image Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Company Info

EXELIXIS INC

1851 Harbor Bay Parkway

Alameda CALIFORNIA 94502 US

CEO: Michael M. Morrissey

Employees: 1147

EXEL Company Website

EXEL Investor Relations

Phone: 16508377000

EXELIXIS INC / EXEL FAQ

What is the stock price of EXELIXIS INC today?

The current stock price of EXEL is 42.86 USD. The price decreased by -1.97% in the last trading session.


What is the ticker symbol for EXELIXIS INC stock?

The exchange symbol of EXELIXIS INC is EXEL and it is listed on the Nasdaq exchange.


On which exchange is EXEL stock listed?

EXEL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EXELIXIS INC stock?

26 analysts have analysed EXEL and the average price target is 38.71 USD. This implies a price decrease of -9.69% is expected in the next year compared to the current price of 42.86. Check the EXELIXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EXELIXIS INC worth?

EXELIXIS INC (EXEL) has a market capitalization of 11.81B USD. This makes EXEL a Large Cap stock.


How many employees does EXELIXIS INC have?

EXELIXIS INC (EXEL) currently has 1147 employees.


What are the support and resistance levels for EXELIXIS INC (EXEL) stock?

EXELIXIS INC (EXEL) has a support level at 42.85. Check the full technical report for a detailed analysis of EXEL support and resistance levels.


Is EXELIXIS INC (EXEL) expected to grow?

The Revenue of EXELIXIS INC (EXEL) is expected to grow by 8.42% in the next year. Check the estimates tab for more information on the EXEL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EXELIXIS INC (EXEL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EXELIXIS INC (EXEL) stock pay dividends?

EXEL does not pay a dividend.


When does EXELIXIS INC (EXEL) report earnings?

EXELIXIS INC (EXEL) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of EXELIXIS INC (EXEL)?

The PE ratio for EXELIXIS INC (EXEL) is 19.48. This is based on the reported non-GAAP earnings per share of 2.2 and the current share price of 42.86 USD. Check the full fundamental report for a full analysis of the valuation metrics for EXEL.


What is the Short Interest ratio of EXELIXIS INC (EXEL) stock?

The outstanding short interest for EXELIXIS INC (EXEL) is 7.12% of its float. Check the ownership tab for more information on the EXEL short interest.


EXEL Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL is one of the better performing stocks in the market, outperforming 96.84% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EXEL Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to EXEL. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EXEL Financial Highlights

Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.2. The EPS increased by 205.56% compared to the year before.


Industry RankSector Rank
PM (TTM) 24.04%
ROA 17.68%
ROE 23.23%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%175%
Sales Q2Q%30.62%
EPS 1Y (TTM)205.56%
Revenue 1Y (TTM)18.49%

EXEL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to EXEL. The Buy consensus is the average rating of analysts ratings from 26 analysts.

For the next year, analysts expect an EPS growth of 22.46% and a revenue growth 8.42% for EXEL


Ownership
Inst Owners91.92%
Ins Owners1.78%
Short Float %7.12%
Short Ratio7.39
Analysts
Analysts76.92
Price Target38.71 (-9.68%)
EPS Next Y22.46%
Revenue Next Year8.42%